Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal L Mackall

Showing results (131-140 of 232) with videos related to

Pageof 24
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2021
Dynamic chromatin regulatory landscape of human CAR T cell exhaustionDavid G Gennert, Rachel C Lynn, Jeff M Granja, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceMichael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumorsMelinda S Merchant, James I Geller, Kristin Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomasCrystal L Mackall, Eunice H Rhee, Elizabeth J Read, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Blood|December 18, 2012
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaWaleed Haso, Daniel W Lee, Nirali N Shah, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell CharacteristicsSandhya R Panch, Sandeep K Srivastava, Nasha Elavia, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2023
Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustionCaroline Lamarche, Kirsten Ward-Hartstonge, Tian Mi, et al.
Cancer|June 14, 2017
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissuesRobbie G Majzner, Jason S Simon, Joseph F Grosso, et al.
Pageof 24

Showing results (131-140 of 232) with videos related to

Sort By:
Pageof 24
Proceedings of the National Academy of Sciences of the United States of America|July 21, 2021
Dynamic chromatin regulatory landscape of human CAR T cell exhaustionDavid G Gennert, Rachel C Lynn, Jeff M Granja, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significanceMichael M Boyiadzis, Madhav V Dhodapkar, Renier J Brentjens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2012
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumorsMelinda S Merchant, James I Geller, Kristin Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomasCrystal L Mackall, Eunice H Rhee, Elizabeth J Read, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
A pan-inhibitor of DASH family enzymes induces immune-mediated regression of murine sarcoma and is a potent adjuvant to dendritic cell vaccination and adoptive T-cell therapyBrynn B Duncan, Steven L Highfill, Haiying Qin, et al.
Blood Advances|August 8, 2022
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomesAiman J Faruqi, John A Ligon, Paul Borgman, et al.
Blood|December 18, 2012
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaWaleed Haso, Daniel W Lee, Nirali N Shah, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2019
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell CharacteristicsSandhya R Panch, Sandeep K Srivastava, Nasha Elavia, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2023
Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustionCaroline Lamarche, Kirsten Ward-Hartstonge, Tian Mi, et al.
Cancer|June 14, 2017
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissuesRobbie G Majzner, Jason S Simon, Joseph F Grosso, et al.
Pageof 24